The Booming Market for Atopic Dermatitis Drugs
The US accounted for nearly half of the atopic dermatitis drugs market in 2021. According to 2021 data from the National Center for Health Statistics, roughly 7% of adults in the U.S. have eczema.
© tang90246 stock.adobe.com
The global atopic dermatitis drugs market was valued at US $6 billion in 2021, according to Transparency Market Research. It’s expected to grow at a compound annual rate of nearly 15%, reaching more than US $29 billion by 2031. The US accounted for nearly half of the atopic dermatitis drugs market in 2021.
A variety of factors are driving the upward trend: More patients, for one. According to 2021 data from the National Center for Health Statistics, roughly 7% of adults in the US have eczema.
And in a study led by the Asthma and Allergy Foundation of America, of the 602 patients who had atopic dermatitis, 60% had mild disease and 40% had moderate or severe disease. Those proportions lead to more awareness of atopic dermatitis as a chronic condition, growing demand for medications, and advances in biologics and targeted therapies.
“The pharmaceutical industry is witnessing substantial investments in research and development for atopic dermatitis drugs,” according to TMR, a global market research company based in Wilmington, Delaware. “Biotechnology and pharmaceutical companies are focusing on developing novel therapeutic options, including targeted biologics, small molecule inhibitors, and immunomodulators. The innovative drugs offer enhanced efficacy and safety profiles, driving adoption and market growth.”
Related: As-Needed Use of Opzelura Can Control Atopic Dermatitis
In a recent market report, TMR noted that the biologics segment grew to 76% of the global market in 2021, with drugs including Incyte’s Opzelura (ruxolitinib) cream 1.5%, a JAK inhibitor; Dupixent (dupilumab/Sanofi Regeneron), a monoclonal antibody targeting IL-4 and IL-13 receptors; and CIBINQO (abrocitinib/Pfizer), an oral JAK inhibitor. The report cited a growing pipeline of biologics (as well as favorable regulatory approvals). Prominent players in the atopic dermatitis drugs industry, it said, are meeting the demand in new ways, such as entering collaborations, partnerships and acquisitions with existing small-, medium- and large-scale providers.
Moreover, the retail pharmacies segment is adding to market growth, in part due to more accessibility, convenience, and prescription dispensing.
What’s down the road? TMR says favorable reimbursement policies and changing lifestyle and environmental factors will likely fuel the market prospects in the near future.
